Eli Lilly, manufacturing plants

Lilly invests $27B to build 4 pharmaceutical manufacturing facilities in the U.S.
With this latest announcement, Lilly has committed to investing more than $50 billion in U.S. manufacturing since 2020.
Eli Lilly to spend billions on new pharmaceutical manufacturing sites
Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.
Eli Lilly plans to invest $27B to build four new US plants as tariffs loom
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.
Eli Lilly expands US manufacturing build-out with $50B target
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.
Eli Lilly To Invest $27B Building 4 New U.S. Manufacturing Sites
Eli Lilly and Co. plans to bolster its domestic medicine production with a $27B investment in four new U.S. pharmaceutical manufacturing sites, bringing its total capital commitment to future expansion to more than $50B.
Eli Lilly Plans to Spend $27 Billion on New U.S. Plants
The pharmaceutical company expects the expansion will create thousands of jobs.
Eli Lilly investing $27B more in US manufacturing
Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.
Eli Lilly wants to make drugs in America. First it wants a tax cut
Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 billion in four new manufacturing sites in the United States. But the company made it clear that those plans hinge on tax cuts.
African drugmaker Aspen says new Latam and Eli Lilly portfolio boosting earnings
By Nqobile Dludla JOHANNESBURG (Reuters) -Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it ...
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
FierceBiotech4d
Eli Lilly feels Magnet's pull with molecular glue deal potentially worth $1.25B
The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.25 billion ...
Eli Lilly takes aim at weight-loss drug copies with new ad campaign
Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...
Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients
Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...
MM&M3d
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
pharmaphorum2h
Lilly uses Oscars ad to warn about 'untested' GLP-1s
It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity ...